On Aug. 11, 2006, Gilead Sciences announced that it had completed its acquisition of Corus Pharma for $365 million. Gilead retained the Corus’ Seattle-based operations, establishing a center of expertise in respiratory therapeutics.

Corus Pharma was founded by Dr. Bruce Montgomery in January 2001 who served as the company’s CEO and Director for five years. Prior to founding Corus, Montgomery was Executive Vice President of Research and Development at PathoGenesis where he managed the development of inhaled tobramycin for the treatment of cystic fibrosis.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.